Showing results (31-40 of 66) with videos related to
Sort By:
Pageof 7
Frontiers in Cardiovascular Medicine|July 28, 2023
Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclaseArpeeta Sharma, Judy Choi, Lachlan Sim, et al.Journal of Science and Medicine in Sport|November 7, 2017
What effect does regular exercise have on oxidative stress in people with Down syndrome? A systematic review with meta-analysesNora Shields, Jenny Downs, Judy B de Haan, et al.Investigative Ophthalmology & Visual Science|February 8, 2018
Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic RetinopathyDevy Deliyanti, Saeed F Alrashdi, Sih Min Tan, et al.International Journal of Cardiology|April 25, 2012
Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE-/- miceAya Matsumoto, Helga D Manthey, Susan A Marsh, et al.Clinical Science (London, England : 1979)|March 24, 2016
A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathyDevy Deliyanti, Jae Young Lee, Steven Petratos, et al.Plos One|July 23, 2013
The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout miceSih Min Tan, Arpeeta Sharma, Derek Y C Yuen, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|March 28, 2009
Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mousePhyllis Chew, Derek Y C Yuen, Philip Koh, et al.Atherosclerosis|November 7, 2015
Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient miceAliki A Rasmiena, Christopher K Barlow, Nada Stefanovic, et al.Clinical Science (London, England : 1979)|January 20, 2022
Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney diseaseJakob A Østergaard, Jay C Jha, Arpeeta Sharma, et al.Journal of Cellular and Molecular Medicine|September 17, 2009
Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivoMandy L Ballinger, Narin Osman, Kazuhiko Hashimura, et al.Pageof 7